Evidence map›Paper›PMID 35628649›Full record

ArticleInternational journal of molecular sciences2022

Study of Oligonucleotides Access and Distribution in Human Peripheral Blood Mononuclear Cells.

Manuel Fernández-Delgado, Luis Sendra, María José Herrero, Gladys G Olivera-Pasquini, Alexander Batista-Duharte, Salvador F Aliño

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Manuel Fernández-DelgadoService of Hematology and Hemotherapy, Hospital General Universitario de Castellón, 12004 Castelló de la Plana, Spain.ORCID 0000-0003-3684-2712
Luis SendraFarmacogenetics and Gene Therapy Group, Instituto de Investigación Sanitaria La Fe, Av. Fernando Abril Martorell, 106, 46026 Valencia, Spain.ORCID 0000-0003-3176-9763
María José HerreroFarmacogenetics and Gene Therapy Group, Instituto de Investigación Sanitaria La Fe, Av. Fernando Abril Martorell, 106, 46026 Valencia, Spain.ORCID 0000-0002-6042-4185
Gladys G Olivera-PasquiniFarmacogenetics and Gene Therapy Group, Instituto de Investigación Sanitaria La Fe, Av. Fernando Abril Martorell, 106, 46026 Valencia, Spain.ORCID 0000-0002-7698-2122
Alexander Batista-DuharteGC01 Immunology and Allergy Group, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menéndez Pidal, s/n, 14004 Córdoba, Spain.ORCID 0000-0002-1875-0518
Salvador F AliñoFarmacogenetics and Gene Therapy Group, Instituto de Investigación Sanitaria La Fe, Av. Fernando Abril Martorell, 106, 46026 Valencia, Spain.ORCID 0000-0002-7830-8713

Funding

Agencia Valenciana de Innovación, Generalitat Valenciana 2021-066-01Asociación Pablo Ugarte 2017/0561
6 · The paper itself

Abstract

Therapeutic oligonucleotides have achieved great clinical interest since their approval as drug agents by regulatory agencies but their access and distribution in blood cells are not completely known. We evaluated by flow cytometry the ability of short fluorescent scramble oligonucleotides (ON*) to access human peripheral blood mononuclear cells (PBMC) after incubating with ON* during 1 h and 7 days of culture follow-up 'in vitro'. Blood samples were treated with chemically modified oligonucleotides (phosphorothioate backbone and 2' O-Me ends) to resist nuclease digestion under culture conditions. The ON* internalization was determined after discarding the membrane-associated fluorescence by trypan blue quenching. Whereas the oligonucleotide accessed neutrophils and monocytes rapidly, achieving their maximum in 1 h and 24 h, respectively, lymphocytes required 7 days to achieve the maximum (80% of cells) transfection. The ON*ability to access lymphocyte types (T, B, and NK) and T cell subtypes (CD4+, CD8+, and CD4-CD8-) were similar, with T cells being more accessible. Regulatory CD4+ and CD8+ T cells were classified in low and high Foxp3 expressers, whose expression proved not to alter the ON* internalization during the first hour, achieving 53% of CD4+Foxp3+ and 40% of CD8+Foxp3+ cells. Our results contribute to understanding and improving the management of therapeutic ONs.

Indexed as

Leukocytes, MononuclearOligonucleotidesCD8-Positive T-LymphocytesForkhead Transcription FactorsHumansLymphocytesForkhead Transcription FactorsOligonucleotidesCD8+ Tregcell uptakeflow cytometryfluorescent labelingFOXP3oligonucleotidesPBMCquenchingTreg

Identifiers

PMID35628649
PMCPMC9143973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.